---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-239015"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-10-14T23:59:59+00:00"
generated_at: "2026-05-17T03:53:09.636298+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Karyopharm closes $131M debt financing; issues 9% convertible notes, waives defaults

## Summary
- Borrowed $12.5M under amended credit agreement; issued $15M 2028 and $103.5M 2029 convertible notes at 9%.
- Specified defaults under existing credit agreement waived via Oct 7, 2025 First Amendment.
- As of Oct 14, 2025, common shares outstanding: 15,926,939.
- Financing includes warrants and pre-funded warrants; previously announced on Oct 8, 2025.

## SEC filing metadata
- accession: 0001193125-25-239015
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-10-14T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/0001193125-25-239015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/d81116d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-239015
- JSON: https://secwatch.observer/filing/0001193125-25-239015.json
- Plain text: https://secwatch.observer/filing/0001193125-25-239015.txt

## Key facts
- Debt Financings
  Karyopharm Therapeutics Inc. incurred credit facility of $12.5 million with term loan lenders at not specified maturing not specified.
  - Instrument: credit facility
  - Principal: $12.5 million
  - Counterparty: term loan lenders
  - Rate: not specified
  - Maturity: not specified
  - Event: incurrence
  source text: On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company borrowed $12.5 million under its credit and guaranty agreement, as amended, by the First Amendment and Waiver to Credit and Guaranty Agreement dated as of October 7, 2025.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/0001193125-25-239015-index.htm
- Debt Financings
  Karyopharm Therapeutics Inc. incurred convertible notes of $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate with holders of convertible notes and other investors at 9.00% maturing 2028 and 2029.
  - Instrument: convertible notes
  - Principal: $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate
  - Counterparty: holders of convertible notes and other investors
  - Rate: 9.00%
  - Maturity: 2028 and 2029
  - Event: incurrence
  source text: On the Closing Date and as disclosed in the Current Report on Form 8-K filed by the Company on October 8, 2025, the Company issued $15.0 million aggregate principal amount of 9.00% senior secured convertible notes due 2028 and $103.5 million aggregate principal amount of 9.00% senior secured convertible notes due 2029.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1503802/000119312525239015/0001193125-25-239015-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.